Aspire Biopharma raises up to $21M via convertible preferred stock; board adds Balatsos

Aspire Biopharma Holdings, Inc.

Initial closing of 13,750 Series A Convertible Preferred Shares for $11M gross proceeds; up to $21M total available.
Preferred shares convertible into common at 80% of lowest 5-day VWAP prior to conversion, subject to 4.99% ownership cap.
Company expects to regain Nasdaq stockholders' equity compliance (min $2.5M) after the offering.
Donald G. Fell resigned from board; Philip Balatsos appointed to fill vacancy.
RBW Capital Partners acted as placement agent; proceeds to support operations and reduce legacy debt.

item 1.01 item 3.02 item 8.01 item 5.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Aspire Biopharma Holdings, Inc. issued up to 25,000 shares of preferred stock to certain accredited investors for $11,000,000 aggregate gross proceeds.

Security: preferred stock
Shares: up to 25,000 shares
Purchaser: certain accredited investors
Consideration: $11,000,000 aggregate gross proceeds

Exact text from the filing

Rule 5636(d) (“ Shareholder Approval ”). Pursuant to the Securities Purchase Agreement, the Company closed on an aggregate of 13,750 Shares resulting in gross proceeds of $11,000,000 including the conversion of $943,801 in existing debt into Shares on the same terms, before deducting fees to be paid to the placement agents and financial advisors of the Company

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Aspire Biopharma Holdings, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at $11,000,000 (effective 2026-02-06).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: $11,000,000
Effective: 2026-02-06

Exact text from the filing

On February 6, 2026, Aspire Biopharma Holdings, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain accredited investors

View on SEC.gov

32 equity issuances filed in the last 30 days. Browse all equity issuances →

Aspire Biopharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-006343

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.